Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC-Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy.

MLA

Shukuya, Takehito, et al. “Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC-Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy.” JTO Clinical and Research Reports, vol. 3, no. 5, Apr. 2022, p. 100320. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2022.100320.

APA

Shukuya, T., Takamochi, K., Sakurai, H., Yoh, K., Hishida, T., Tsuboi, M., Goto, Y., Kudo, Y., Ohde, Y., Okumura, S., Taguri, M., & Kunitoh, H. (2022). Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC-Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy. JTO Clinical and Research Reports, 3(5), 100320. https://doi.org/10.1016/j.jtocrr.2022.100320

Chicago

Shukuya, Takehito, Kazuya Takamochi, Hiroyuki Sakurai, Kiyotaka Yoh, Tomoyuki Hishida, Masahiro Tsuboi, Yasushi Goto, et al. 2022. “Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC-Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy.” JTO Clinical and Research Reports 3 (5): 100320. doi:10.1016/j.jtocrr.2022.100320.